您的位置: 首页 > 2021年11月 第52卷 第6期 > 文字全文
2023年7月 第38卷 第7期11
目录

乳腺癌化疗患者完全输液港相关血栓形成的因素分析

Analysis of factors of venous thrombosis among breast cancer patients with totally implantable access port for chemotherapy

来源期刊: 广州医药 | 54-58 发布时间:2021-11-26 收稿时间:2025/11/13 18:01:36 阅读量:12
作者:
关键词:
完全植入式输液港导管相关血栓形成雌激素受体人表皮生长因子受体-2
totally implantable access portcatheter-related thrombosisestrogen recepterhuman epidermal growth facter recepter-2
DOI:
10.3969/j.issn.1000-8535.2021.06.011
收稿时间:
2021-06-02 
修订日期:
 
接收日期:
 
引用总数:
0  
目的 回顾性分析因化疗需要行完全植入式输液港的乳腺癌患者相关血栓形成的因素。方法 收集广州市第一人民医院乳腺外科2018年5月—2019年4月期间行植入式输液港置入术的60例乳腺癌患者相关资料,采用SPSS 26.0软件进行统计学分析。结果 输液港相关血栓形成(catheter related thrombosis,CRT)发生率为21/60(35%)。BMI≤24的患者CRT发生率为30.3%,BMI>24则为40.74%;行4、6、8次化疗的CRT发生率分别为20%、33.34%、44.12%,导管末端位于T5-T8的CRT发生分别为:66.67%, 26.09%, 28.57%, 50%;Ki-67高表达的血栓发生率为27.5%,低Ki-67表达则为50%;导管材质为聚氨酯的血栓发生率为47.62%,硅胶材质则为28.21%,但差异均无统计学意义(P>0.05)。雌激素受体/孕激素受体(estragen receptor/progesterone receptor,ER/PR)阴性的CRT发生率为60%,ER/PR阳性则为23.8%(P<0.05);人表皮生长因子受体-2(human epidermal growth factor receptor-2,HER-2)阳性CRT发生率为50%,HER-2阴性CRT发生率则为23.53%(P<0.05)。多因素分析:相对于ER/PR阳性,ER/PR阴性将增加CRT的发生(OR=4.482, 95%CI:1.116~17.998, P<0.05);Ki-67的表达对血栓形成的影响具有统计学意义(OR=7.051, 95%CI:1.513~32.858, P<0.05);HER-2表达对CRT的形成均无统计学意义(OR=0.254,95%CI:0.058~1.115, P>0.05)。结论 血栓形成是植入式输液港术后常见的并发症,与肿瘤ER/PR表达相关,临床上应得到重视。
Objective To analyse the factors that lead to venous thrombosis among breast cancer patients who need totally implantable access port(TIAP) for chemotherapy. Methods Collecting the clinical data of 60 breast patients admitted to Guanzhou First People's Hospital from May 2018 to April 2019, analysed with SPSS 26.0. Results Catheter-related thrombosis(CRT) occurred in 21 out of 60(35%) patients with TIAP. 30.3% patients with BMI≤24 and 40.74% patients with BMI>24 had CRT, and incidences of CRT were 20%, 33.34%, 44.12% at the fourth, sixth, eighth therapy respectively. The access terminal position at T5-T8 had 66.67%, 26.09%, 28.57%, 50% of incidence for CRT respectively. 27.5% CRT was with high Ki-67 expression and 50% CRT was with low Ki-67 expression; 47.62% patients with polyurethane catheter and 28.21% patients with silicone catheter got CRT. There were no significant differences in the comparisons above. CRT incidence in ER/PR negative patients was 60%,while 23.08% in ER/PR positive patients (P<0.05). In HER-2 positive and negative patients, the incidences of CRT were 50% and 23.53% (P<0.05). Logistic regression noticed that ER/PR negative would increase the incidence of CRT(OR=4.482, 95%CI:1.116~17.998, P<0.05), low Ki-67 expression would accelerate CRT(OR=7.051, 95%CI:1.513~32.858, P<0.05). There was no significant difference in the formation of CRT with HER-2 expression(OR=0.254, 95%CI:0.058~1.115, P>0.05). Conclusion CRT was a common complication of TIAP, which related with ER/PR expression, and should pay attention to during clinical practices.
1、 蒋凤莲,杨伟洪,黄文宇.乳腺癌患者血浆D-二聚体水平与乳腺癌组织中Ki-67表达的相关性[J]. 中国实用医药,2021,16(13):24-27. 蒋凤莲,杨伟洪,黄文宇.乳腺癌患者血浆D-二聚体水平与乳腺癌组织中Ki-67表达的相关性[J]. 中国实用医药,2021,16(13):24-27.
2、 韩晶, 王培军, 汤如勇,等. HER-2基因在乳腺癌中的表达及其与雌激素受体亚型的关系[J]. 第二军医大学学报, 2006, 27(11): 1268-1269. 韩晶, 王培军, 汤如勇,等. HER-2基因在乳腺癌中的表达及其与雌激素受体亚型的关系[J]. 第二军医大学学报, 2006, 27(11): 1268-1269.
3、 SCHROTH W,WINTER S,BUTTNER F,et al. Clinical outcome and global gene expression data support the existence of the estrogen receptor-negative /progesterone receptor-positive invasive breast cancer phenotype[J]. Breast Cancer Res Treat,2016, 155(1) : 85-97. SCHROTH W,WINTER S,BUTTNER F,et al. Clinical outcome and global gene expression data support the existence of the estrogen receptor-negative /progesterone receptor-positive invasive breast cancer phenotype[J]. Breast Cancer Res Treat,2016, 155(1) : 85-97.
4、 WOOD S C, TANG X, TESFAMARIAM B. Paclitaxel potentiates in flammatory cytokine-induced prothrommbotic molecules in endothelial cells[J]. J Cardiovasc Pharmacol, 2010, 55(3): 276-285. WOOD S C, TANG X, TESFAMARIAM B. Paclitaxel potentiates in flammatory cytokine-induced prothrommbotic molecules in endothelial cells[J]. J Cardiovasc Pharmacol, 2010, 55(3): 276-285.
5、 张进泓,罗凤.3380例乳腺癌患者放置完全植入式静脉输液港化疗的并发症分析[J]. 中华乳腺病杂志(电子版),2019,13(6):350-355. 张进泓,罗凤.3380例乳腺癌患者放置完全植入式静脉输液港化疗的并发症分析[J]. 中华乳腺病杂志(电子版),2019,13(6):350-355.
6、 CAERS J, FONTAINE C, VINH-HUNG V, et al. Catheter tip position as a risk factor for thrombosis associated with the use of subcutaneous infusion ports[J]. Support CareCancer, 2005, 13(5): 325-331. CAERS J, FONTAINE C, VINH-HUNG V, et al. Catheter tip position as a risk factor for thrombosis associated with the use of subcutaneous infusion ports[J]. Support CareCancer, 2005, 13(5): 325-331.
7、 毛美芬, 徐亚文, 高雪娟, 等. 乳腺癌化疗患者输液港相关血栓形成的影响因素[J]. 护理学杂志, 2019, 34(1): 33-35. 毛美芬, 徐亚文, 高雪娟, 等. 乳腺癌化疗患者输液港相关血栓形成的影响因素[J]. 护理学杂志, 2019, 34(1): 33-35.
8、 WILDGRUBER M, BORGMEYER S, HALLER B, et al. Short-term and long-term outcome of radiological-guided insertionof central venous access port devices implanted at the forearm: a retrospective monocenter analysis in 1704 patients[J]. Eur Radiol, 2015,(25):606-616. WILDGRUBER M, BORGMEYER S, HALLER B, et al. Short-term and long-term outcome of radiological-guided insertionof central venous access port devices implanted at the forearm: a retrospective monocenter analysis in 1704 patients[J]. Eur Radiol, 2015,(25):606-616.
9、 ALMASI-SPERLING V, HIEBER S, LERMANN J, et al. Femoralplacement of totally implantable venous access ports in patients with bilateral breast cancer[J]. Geburtshilfe Frauenheilkd, 2016(76):53-58. ALMASI-SPERLING V, HIEBER S, LERMANN J, et al. Femoralplacement of totally implantable venous access ports in patients with bilateral breast cancer[J]. Geburtshilfe Frauenheilkd, 2016(76):53-58.
10、 中心静脉通路上海协作组. 完全植入式输液港上海专家共识[J]. 介入放射学杂志, 2015, 24(12): 1029-1033. 中心静脉通路上海协作组. 完全植入式输液港上海专家共识[J]. 介入放射学杂志, 2015, 24(12): 1029-1033.
11、 宋仲学,刘健,张佩佩, 等.彩色多普勒引导下完全埋入式静脉输液港颈内静脉植入术的有效性和安全性[J]. 现代肿瘤医学,2021,29(14):2506-2509. 宋仲学,刘健,张佩佩, 等.彩色多普勒引导下完全埋入式静脉输液港颈内静脉植入术的有效性和安全性[J]. 现代肿瘤医学,2021,29(14):2506-2509.
12、 GURKAN S, SEBER S, GUR O, et a1. Retrospective evaluation of totally implantable venous access port devices: early and late complications[J]. J BUON, 2015, 20(1): 338-345. GURKAN S, SEBER S, GUR O, et a1. Retrospective evaluation of totally implantable venous access port devices: early and late complications[J]. J BUON, 2015, 20(1): 338-345.
13、 孙玉巧,周涛,李云涛,等. 完全植入式静脉输液港的临床应用[J]. 中华外科杂志,2014,52(8): 608-611. 孙玉巧,周涛,李云涛,等. 完全植入式静脉输液港的临床应用[J]. 中华外科杂志,2014,52(8): 608-611.
14、 TORRE L A, BRAY F, SIEGEL R L, et al. Global cancer statistics, 2012[J]. Ca-Cancer J Clin, 2015, 65(2): 87-108. TORRE L A, BRAY F, SIEGEL R L, et al. Global cancer statistics, 2012[J]. Ca-Cancer J Clin, 2015, 65(2): 87-108.
15、 SIU A L. Screening for breast cancer: U.S. preventive services task forcere commendation statement[J]. Ann Int Med, 2016, 164 (4) :279-296. SIU A L. Screening for breast cancer: U.S. preventive services task forcere commendation statement[J]. Ann Int Med, 2016, 164 (4) :279-296.
上一篇
下一篇
出版者信息








《广州医药》公众号
目录